The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample

Schultz, Rodrigo Rizek; Siviero, Marilena Occhini; Bertolucci, Paulo Henrique Ferreira

doi:10.1590/s0100-879x2001001000009

Cited by 70 publications

(69 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This aspect has motivated the choice of the instrument as well as be available for use free of charge. Furthermore, it may be administered from 30 to 45 minutes 10 . The immediate recall of words is composed of a list of ten words in which the participant is asked to read them aloud and to try to memorize them.…”

Section: Methodsmentioning

confidence: 99%

Perfil dos usuários de AASI com vistas à amplificação, cognição e processamento auditivo

Viacelli¹,

Costa-Ferreira

2012

Rev. CEFAC

View full text Add to dashboard Cite

OBJETIVO: estabelecer o perfil dos usuários de AASI atendidos no Centro de Saúde Auditiva com vistas à amplificação, cognição e processamento auditivo (PA). MÉTODO: participaram do estudo 59 sujeitos com idades entre 41 e 92 anos. Na primeira etapa, realizou-se a coleta dos dados dos prontuários: dados das avaliações audiológica e otorrinolaringológica, anamnese, teste de fala com o AASI em uso, dados do molde e do AASI, orientações recebidas e resultados do treinamento auditivo. Na segunda etapa, foram realizados os testes de Dicótico de Dígitos (DD) e Teste de Padrão de Frequência (TPF), Avaliação da Doença de Alzheimer-Cognitiva (ADAS-Cog) e a Escala de Depressão Geriátrica (EDG-15). Nessa etapa, participaram 47 sujeitos. RESULTADOS: em relação à idade, 67,80% tem 60 anos ou mais. Os aspectos mais relatados na anamnese foram tontura e zumbido e exposição ao ruído. Na avaliação audiológica, identificou-se perda auditiva neurossensorial de grau moderado e curva descendente como os mais frequentes, coincidindo com os achados imitanciométricos: curva tipo A com reflexos ausentes. No treinamento auditivo, as habilidades que mais apresentaram alterações foram identificação e compreensão. Nos testes DD e TPF, as médias de acertos ficaram abaixo dos padrões de normalidade. No ADAS-Cog, os maiores escores foram palavra evocada, reconhecimento de palavra e compreensão. No EDG, 20 sujeitos apresentam características sugestivas de depressão. CONCLUSÃO: foi possível estabelecer o perfil dos usuários de AASI com vistas à amplificação, cognição e ao PA.

show abstract

Section: Methodsmentioning

confidence: 99%

Perfil dos usuários de AASI com vistas à amplificação, cognição e processamento auditivo

Viacelli¹,

Costa-Ferreira

2012

Rev. CEFAC

View full text Add to dashboard Cite

show abstract

“…The secondary efficacy measure was the performance in the Brazilian version of the Alzheimer's disease Assessment Scale Cognitive Subscale (ADAS-Cog) 22 . The ADAS-Cog is widely used in clinical trials for the evaluation of treatment effects in AD.…”

Section: Methodsmentioning

confidence: 99%

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01)

Caramelli

Chaves

Engelhardt

et al. 2004

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Objective: To investigate the effects of galantamine on the performance of patients with mild to moderate Alzheimer's disease (AD) in a computerized neuropsychological test battery (CNTB). Method:Thirty-three patients with probable AD were treated with galantamine for three months and evaluated in a prospective, open-label, multi-center study. The CNTB and the ADAS-Cog were administered at baseline and after 12 weeks. The CNTB includes reaction time tests to evaluate attention, implicit and episodic memory for faces and words. Statistical comparisons were performed between the results in week 12 versus baseline. Patients who did not reach the therapeutic doses were excluded from the efficacy analysis. Results: Four patients (12.1%) were excluded from the analysis either because of treatment discontinuation (n=3) or because a therapeutic dose was not reached (n=1).The remaining 29 patients were treated with doses of 24 mg/day (n=22) and 16 mg/day (n=7). After 12 weeks, significant reductions in reaction time were seen in the test of episodic memory for faces (p=0.023) and in the test of two-choice reaction time (p=0.039) of the CNTB. Conclusion: Treatment with galantamine produced improvement in computerized tests of attention and episodic memory after 12 weeks, leading to statistically significant reduction in the reaction times.KEY WORDS: Alzheimer's disease, clinical trial, galantamine, computerized neuropsychological tests, attention, memory. Efeitos da galantamina sobre a memória e a atenção na doença de Alzheimer medidos por testes neuropsicológicos computadorizados: resultados do Estudo Multicêntrico com Galantamina (GAL-BRA-01)RESUMO -Objetivo: Investigar os efeitos da galantamina no desempenho de pacientes portadores de doença de Alzheimer (DA) leve a moderada em uma bateria de testes neuropsicológicos computadorizados (BTNC). Método: Trinta e três pacientes com DA provável receberam tratamento com galantamina por três meses em ensaio clínico multicêntrico aberto e prospectivo. A escala BTNC e a ADAS-Cog foram administradas no início e ao final de 12 semanas. A BTNC incluiu testes de tempo de reação avaliando atenção, memória implícita e memória episódica para palavras e faces. Comparações estatísticas foram realizadas entre os resultados na 12ª semana versus a linha de base. Pacientes que não atingiram dose terapêutica foram excluídos da análise. Resultados: Quatro pacientes (12,1%) foram excluídos por interrupção do tratamento (n=3) ou por não atingir dose terapêutica (n=1). Os 29 pacientes remanescentes foram tratados com doses de 24 mg/dia (n=22) e 16 mg/dia (n=7). Ao final de 12 semanas, reduções nos tempos de reação foram observadas nos testes de memória episódica para faces (p=0,023) e no teste de tempo de reação de dupla

show abstract

“…We also applied the Alzheimer Disease Assessment Scale -Cognitive Subscale 19 , which assesses the intensity of cognitive changes. The cognitive subscale includes 11 items, with a maximum score of 70.…”

Section: ) Cognitionmentioning

confidence: 99%

“…The cognitive subscale includes 11 items, with a maximum score of 70. Higher scores indicate a poor performance 19 .…”

Section: ) Cognitionmentioning

confidence: 99%

MacArthur Competence Assessment Tool for Treatment in Alzheimer disease: cross-cultural adaptation

Santos

Sousa

Neto

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective: We adapted the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) to Brazilian Portuguese, pilot testing it on mild and moderate patients with Alzheimer's disease (AD). Methods: The cross-cultural process required six steps. Sixty-six patients with AD were assessed for competence to consent to treatment, global cognition, working memory, awareness of disease, functionality, depressive symptoms and dementia severity. Results: The items had semantic, idiomatic, conceptual and experiential equivalence. We found no difference between mild and moderate patients with AD on the MacCAT-T domains. The linear regressions showed that reasoning (p = 0.000) and functional status (p = 0.003) were related to understanding. Understanding (p = 0.000) was related to appreciation and reasoning. Awareness of disease (p = 0.001) was related to expressing a choice. Conclusions: The MacCAT-T adaptation was well-understood and the constructs of the original version were maintained. The results of the pilot study demonstrated an available Brazilian tool focused on decision-making capacity in AD.

show abstract

The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample

Cited by 70 publications

References 19 publications

Perfil dos usuários de AASI com vistas à amplificação, cognição e processamento auditivo

Perfil dos usuários de AASI com vistas à amplificação, cognição e processamento auditivo

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01)

MacArthur Competence Assessment Tool for Treatment in Alzheimer disease: cross-cultural adaptation

Contact Info

Product

Resources

About